Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 260

1.

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.

Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N.

Oncogene. 2018 Sep;37(39):5257-5268. doi: 10.1038/s41388-018-0347-4. Epub 2018 May 31.

2.

Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.

Aoyama-Kikawa S, Fujita H, Hanley SJB, Kasamo M, Kikuchi K, Torigoe T, Matsuno Y, Tamakoshi A, Sasaki T, Matsuura M, Kato Y, Dong P, Watari H, Saito T, Sengoku K, Sakuragi N.

Cancer Sci. 2018 Jun;109(6):2003-2012. doi: 10.1111/cas.13608. Epub 2018 May 31.

3.

The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.

Nakatani M, Watari H, Mitamura T, Wang L, Hatanaka Y, Hatanaka KC, Honda K, Nomura T, Nishihara H, Tanaka S, Sakuragi N.

Anticancer Res. 2017 Nov;37(11):6125-6132.

PMID:
29061793
4.

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3).

Watari H, Katayama H, Shibata T, Ushijima K, Satoh T, Onda T, Aoki D, Fukuda H, Yaegashi N, Sakuragi N; Gynecologic Cancer Study Group of the Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2017 Oct 1;47(10):986-990. doi: 10.1093/jjco/hyx108.

PMID:
28981739
5.

Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis.

Zhang Q, Dong P, Liu X, Sakuragi N, Guo SW.

Sci Rep. 2017 Jul 28;7(1):6804. doi: 10.1038/s41598-017-06920-7.

6.

Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).

Ohnishi S, Watari H, Kanno M, Ohba Y, Takeuchi S, Miyaji T, Oyamada S, Nomura E, Kato H, Sugiyama T, Asaka M, Sakuragi N, Yamaguchi T, Uezono Y, Iwase S.

J Gynecol Oncol. 2017 Sep;28(5):e44. doi: 10.3802/jgo.2017.28.e44. Epub 2017 Mar 17.

7.

Loss of luteotropic prostaglandin E plays an important role in the regulation of luteolysis in women.

Nio-Kobayashi J, Kudo M, Sakuragi N, Iwanaga T, Duncan WC.

Mol Hum Reprod. 2017 May 1;23(5):271-281. doi: 10.1093/molehr/gax011.

PMID:
28333263
8.

EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis.

Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N.

Oncotarget. 2017 Feb 21;8(8):13509-13520. doi: 10.18632/oncotarget.14586.

9.

Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Suzuki F, Yamada T, Kudo M, Yue J, Sakuragi N.

Sci Rep. 2016 Oct 21;6:35480. doi: 10.1038/srep35480.

10.

Challenges in breast and cervical cancer control in Japan.

Hanley SJ, Fujita H, Tamakoshi A, Dong P, Sakuragi N.

Lancet Oncol. 2016 Sep;17(9):e372. doi: 10.1016/S1470-2045(16)30411-9. Epub 2016 Aug 30. No abstract available.

PMID:
27599140
11.

MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells.

Dong P, Xiong Y, Watari H, Hanley SJ, Konno Y, Ihira K, Yamada T, Kudo M, Yue J, Sakuragi N.

J Exp Clin Cancer Res. 2016 Sep 5;35(1):132. doi: 10.1186/s13046-016-0415-y.

12.

Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells.

Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI.

Cancer Res. 2016 Oct 15;76(20):6030-6042. Epub 2016 Aug 22.

13.

Paneth cell α-defensins and enteric microbiota in health and disease.

Nakamura K, Sakuragi N, Takakuwa A, Ayabe T.

Biosci Microbiota Food Health. 2016;35(2):57-67. doi: 10.12938/bmfh.2015-019. Epub 2015 Nov 26. Review.

14.

Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression.

Dong P, Ihira K, Xiong Y, Watari H, Hanley SJ, Yamada T, Hosaka M, Kudo M, Yue J, Sakuragi N.

Oncotarget. 2016 Apr 12;7(15):20260-70. doi: 10.18632/oncotarget.7754.

15.

HPV self-sampling in Japanese women: A feasibility study in a population with limited experience of tampon use.

Hanley SJ, Fujita H, Yokoyama S, Kunisawa S, Tamakoshi A, Dong P, Kobayashi N, Watari H, Kudo M, Sakuragi N.

J Med Screen. 2016 Sep;23(3):164-70. doi: 10.1177/0969141315625702. Epub 2016 Feb 25.

PMID:
26919866
16.

Comparison between borderline ovarian tumors and carcinomas using semi-automated histogram analysis of diffusion-weighted imaging: focusing on solid components.

Mimura R, Kato F, Tha KK, Kudo K, Konno Y, Oyama-Manabe N, Kato T, Watari H, Sakuragi N, Shirato H.

Jpn J Radiol. 2016 Mar;34(3):229-37. doi: 10.1007/s11604-016-0518-6. Epub 2016 Jan 21.

PMID:
26798066
17.

Aminopeptidase N (APN/CD13) as a target molecule for scirrhous gastric cancer.

Nohara S, Kato K, Fujiwara D, Sakuragi N, Yanagihara K, Iwanuma Y, Kajiyama Y.

Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):494-503. doi: 10.1016/j.clinre.2015.11.003. Epub 2016 Jan 13.

PMID:
26774363
18.

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors.

Dong P, Ihira K, Hamada J, Watari H, Yamada T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N.

Oncotarget. 2015 Aug 21;6(24):19968-75. Review.

19.

Regulated C-C motif ligand 2 (CCL2) in luteal cells contributes to macrophage infiltration into the human corpus luteum during luteolysis.

Nio-Kobayashi J, Kudo M, Sakuragi N, Kimura S, Iwanaga T, Duncan WC.

Mol Hum Reprod. 2015 Aug;21(8):645-54. doi: 10.1093/molehr/gav028. Epub 2015 May 23.

PMID:
26003810
20.

Human papillomavirus type 16 sequence variation in concurrent vulvar and penile carcinoma in a married couple.

Mitamura T, Watari H, Yamashiro K, Kato T, Hosaka M, Shimada C, Fukumoto S, Noshiro K, Sasaki T, Sakuragi N.

Sex Transm Dis. 2015 Jun;42(6):342-3. doi: 10.1097/OLQ.0000000000000274.

PMID:
25970313
21.

Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer.

Todo Y, Kato H, Okamoto K, Minobe S, Yamashiro K, Sakuragi N.

J Gynecol Oncol. 2016 Jan;27(1):e1. doi: 10.3802/jgo.2016.27.e1. Epub 2015 Nov 23.

22.

P18/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane.

Hassan MK, Watari H, Mitamura T, Mohamed Z, El-Khamisy SF, Ohba Y, Sakuragi N.

Oncoscience. 2015 Mar 23;2(3):294-308. eCollection 2015.

23.

Nerve-sparing radical hysterectomy: time for a new standard of care for cervical cancer?

Sakuragi N.

J Gynecol Oncol. 2015 Apr;26(2):81-2. doi: 10.3802/jgo.2015.26.2.81. No abstract available.

24.

Bone morphogenetic proteins are mediators of luteolysis in the human corpus luteum.

Nio-Kobayashi J, Trendell J, Giakoumelou S, Boswell L, Nicol L, Kudo M, Sakuragi N, Iwanaga T, Duncan WC.

Endocrinology. 2015 Apr;156(4):1494-503. doi: 10.1210/en.2014-1704. Epub 2015 Jan 30.

PMID:
25635621
25.

Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.

Satoh T, Aoki Y, Kasamatsu T, Ochiai K, Takano M, Watanabe Y, Kikkawa F, Takeshima N, Hatae M, Yokota H, Saito T, Yaegashi N, Kobayashi H, Baba T, Kodama S, Saito T, Sakuragi N, Sumi T, Kamura T, Yoshikawa H.

Eur J Cancer. 2015 Feb;51(3):340-51. doi: 10.1016/j.ejca.2014.12.004. Epub 2015 Jan 2.

PMID:
25559616
26.

FDG PET/CT diagnostic criteria may need adjustment based on MRI to estimate the presurgical risk of extrapelvic infiltration in patients with uterine endometrial cancer.

Sudo S, Hattori N, Manabe O, Kato F, Mimura R, Magota K, Sugimori H, Hirata K, Sakuragi N, Tamaki N.

Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):676-84. doi: 10.1007/s00259-014-2964-7. Epub 2014 Dec 13.

PMID:
25504022
27.

MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.

Konno Y, Dong P, Xiong Y, Suzuki F, Lu J, Cai M, Watari H, Mitamura T, Hosaka M, Hanley SJ, Kudo M, Sakuragi N.

Oncotarget. 2014 Aug 15;5(15):6049-62.

28.

Lymphadenectomy can be omitted for low-risk endometrial cancer based on preoperative assessments.

Mitamura T, Watari H, Todo Y, Kato T, Konno Y, Hosaka M, Sakuragi N.

J Gynecol Oncol. 2014 Oct;25(4):301-5. doi: 10.3802/jgo.2014.25.4.301. Epub 2014 Jun 18.

29.

The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.

Dong P, Konno Y, Watari H, Hosaka M, Noguchi M, Sakuragi N.

J Transl Med. 2014 Aug 21;12:231. doi: 10.1186/s12967-014-0231-0. Review.

30.

Apoptosis and molecular targeting therapy in cancer.

Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N.

Biomed Res Int. 2014;2014:150845. doi: 10.1155/2014/150845. Epub 2014 Jun 12. Review.

31.

microRNA 31 functions as an endometrial cancer oncogene by suppressing Hippo tumor suppressor pathway.

Mitamura T, Watari H, Wang L, Kanno H, Kitagawa M, Hassan MK, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N.

Mol Cancer. 2014 Apr 29;13:97. doi: 10.1186/1476-4598-13-97.

32.

Genital infection caused by Entamoeba histolytica confirmed by polymerase chain reaction analyses.

Asano H, Kaneuchi M, Furuta I, Yamaya Y, Hatanaka KC, Takeda M, Matsuno Y, Sakuragi N.

J Obstet Gynaecol Res. 2014 May;40(5):1441-4. doi: 10.1111/jog.12351. Epub 2014 Apr 21.

PMID:
24750396
33.

Histone deacetylase inhibitors sensitize lung cancer cells to hyperthermia: involvement of Ku70/SirT-1 in thermo-protection.

Hassan MK, Watari H, Salah-Eldin AE, Sultan AS, Mohamed Z, Fujioka Y, Ohba Y, Sakuragi N.

PLoS One. 2014 Apr 11;9(4):e94213. doi: 10.1371/journal.pone.0094213. eCollection 2014.

34.

Distribution of lymph node metastasis sites in endometrial cancer undergoing systematic pelvic and para-aortic lymphadenectomy: a proposal of optimal lymphadenectomy for future clinical trials.

Odagiri T, Watari H, Kato T, Mitamura T, Hosaka M, Sudo S, Takeda M, Kobayashi N, Dong P, Todo Y, Kudo M, Sakuragi N.

Ann Surg Oncol. 2014 Aug;21(8):2755-61. doi: 10.1245/s10434-014-3663-0. Epub 2014 Apr 5.

PMID:
24705578
35.

Refining insight into cervical cancer progression.

Sakuragi N.

Lancet Oncol. 2014 Apr;15(4):371-2. doi: 10.1016/S1470-2045(14)70085-3. Epub 2014 Mar 19. No abstract available.

PMID:
24656438
36.

An exploratory study of Japanese fathers' knowledge of and attitudes towards HPV and HPV vaccination: does marital status matter?

Hanley SJ, Yoshioka E, Ito Y, Konno R, Sasaki Y, Kishi R, Sakuragi N.

Asian Pac J Cancer Prev. 2014;15(4):1837-43.

37.

Tailoring lymphadenectomy according to the risk of lymph node metastasis in endometrial cancer.

Todo Y, Watari H, Kang S, Sakuragi N.

J Obstet Gynaecol Res. 2014 Feb;40(2):317-21. doi: 10.1111/jog.12309.

PMID:
24472049
38.

Proposal of a concept and design of a randomized phase III trial investigating the survival effect of para-aortic lymphadenectomy in endometrial cancer.

Watari H, Todo Y, Kang S, Odagiri T, Sakuragi N.

J Obstet Gynaecol Res. 2014 Feb;40(2):312-6. doi: 10.1111/jog.12305.

PMID:
24472048
39.

Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer.

Ebina Y, Watari H, Kaneuchi M, Takeda M, Hosaka M, Kudo M, Yamada H, Sakuragi N.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):446-51. doi: 10.1007/s00259-013-2610-9. Epub 2013 Nov 13.

PMID:
24221243
40.

Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer.

Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X, Guo SW, Ju J, Jia N, Konno Y, Watari H, Hosaka M, Sudo S, Sakuragi N.

Carcinogenesis. 2014 Apr;35(4):760-8. doi: 10.1093/carcin/bgt369. Epub 2013 Nov 11.

PMID:
24220291
41.

Prognostic significance of miR-194 in endometrial cancer.

Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J.

Biomark Res. 2013;1. pii: 12. doi: 10.1186/2050-7771-1-12.

42.

MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.

Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N.

Mol Carcinog. 2014 May;53(5):349-59. doi: 10.1002/mc.21983. Epub 2013 Sep 3.

PMID:
24002805
43.

A monoclonal antibody-based sandwich enzyme-linked immunosorbent assay for detection of secreted α-defensin.

Nakamura K, Sakuragi N, Ayabe T.

Anal Biochem. 2013 Dec 15;443(2):124-31. doi: 10.1016/j.ab.2013.08.021. Epub 2013 Aug 28.

PMID:
23994564
44.

Clinical significance of tumor volume in endometrial cancer: a Japan-Korea cooperative study.

Todo Y, Choi HJ, Kang S, Kim JW, Nam JH, Watari H, Tamakoshi A, Sakuragi N.

Gynecol Oncol. 2013 Nov;131(2):294-8. doi: 10.1016/j.ygyno.2013.08.008. Epub 2013 Aug 14.

PMID:
23954595
45.

Multivariate prognostic analysis of adenocarcinoma of the uterine cervix treated with radical hysterectomy and systematic lymphadenectomy.

Kato T, Watari H, Takeda M, Hosaka M, Mitamura T, Kobayashi N, Sudo S, Kaneuchi M, Kudo M, Sakuragi N.

J Gynecol Oncol. 2013 Jul;24(3):222-8. doi: 10.3802/jgo.2013.24.3.222. Epub 2013 Jul 4.

46.

Emerging therapeutic biomarkers in endometrial cancer.

Dong P, Kaneuchi M, Konno Y, Watari H, Sudo S, Sakuragi N.

Biomed Res Int. 2013;2013:130362. doi: 10.1155/2013/130362. Epub 2013 Jun 11. Review.

48.

Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET.

Mitamura T, Watari H, Wang L, Kanno H, Hassan MK, Miyazaki M, Katoh Y, Kimura T, Tanino M, Nishihara H, Tanaka S, Sakuragi N.

Oncogenesis. 2013 Mar 25;2:e40. doi: 10.1038/oncsis.2013.3.

49.

Methodological considerations in the analysis of the therapeutic significance of lymphadenectomy in endometrial cancer.

Todo Y, Sakuragi N.

Taiwan J Obstet Gynecol. 2013 Mar;52(1):8-13. doi: 10.1016/j.tjog.2013.01.003. Review.

50.

Tumor volume successively reflects the state of disease progression in endometrial cancer.

Todo Y, Watari H, Okamoto K, Hareyama H, Minobe S, Kato H, Sakuragi N.

Gynecol Oncol. 2013 Jun;129(3):472-7. doi: 10.1016/j.ygyno.2013.02.034. Epub 2013 Mar 5.

PMID:
23474346

Supplemental Content

Loading ...
Support Center